サンプル依頼リスト カート
  • English
  • Korean
表紙：咽頭炎治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1345384

咽頭炎治療薬の世界市場-2023年～2030年

Global Pharyngitis Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
咽頭炎治療薬の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の咽頭炎治療薬市場は、2022年に23億米ドルに達し、2023～2030年の予測期間中にCAGR 4.5%で成長し、2030年には32億米ドルに達すると予測されます。

世界の咽頭炎治療薬市場は近年著しい成長と変貌を遂げており、有病率の増加、新規治療薬に対する需要の増加、臨床試験の増加など、そのダイナミクスに影響を与える様々な要因があります。新規治療法に対する政府の投資は、世界市場を引き続き牽引し、押し上げるでしょう。世界の咽頭炎治療薬業界は、その影響を軽減することにますます重点を置いています。

咽頭炎は喉の痛みとしても知られ、急性咽頭炎と慢性咽頭炎の2種類があります。治療は病気の種類と重症度に基づいて行われます。咽頭炎の治療には、抗生物質、非ステロイド性抗炎症薬、抗真菌薬、抗ウイルス薬、副腎皮質ステロイド薬、鎮咳薬など多くの薬剤が使用されます。しかし、抗生物質は第一選択薬と考えられています。同様に、北米は高度な医療インフラと大手企業の存在により、最大の市場シェアを獲得して世界市場を独占しています。

咽頭炎の有病率の増加、意識の高まり、新規治療薬に対する需要の増加、治験の増加、個別化医薬品の採用の増加、一般用医薬品（OTC）に対する需要の増加、治療オプションの進歩が、予測期間中に市場を牽引すると予想される主な要因です。

市場力学

新規治療薬への需要増加が咽頭炎治療薬市場の成長を牽引すると予測

新規治療薬に対する需要の高まりが、予測期間中の世界市場を牽引すると期待されています。現在利用可能な咽頭炎治療薬は、特に抗生物質が最も広く使用されていますが、これらの薬剤に伴う副作用もあります。新しい治療薬は患者の予後を改善するために継続的に進化しており、副作用の少ない革新的な製品に対する需要が継続的に高まっています。

例えば、2022年5月16日、ヴイックスはインドでヴイックス・トゥルシ咳止めを発売すると発表しました。トゥルシーの香りを製品群に加えることで、同ブランドは、何世代にもわたって受け継がれてきた伝統的な治療法を、他の薬に比べて副作用が極めて少なく、誰にとっても便利で利用しやすいものにするという目的を再確認しています。

さらに、咽頭炎治療薬に関する継続的な研究活動は、より良い治療の機会を高め、革新的な治療アプローチの研究開発は、子供を含むすべての年齢層に非常に適した潜在的な新規治療法の発見につながっています。このような進歩は、異なる作用機序を持つ新薬のイントロダクションへの道を広げます。

例えば、2021年2月11日、Honibe社は、喉の痛みを自然に和らげる初の（最高）純度99％の子供用蜂蜜ロリポップ、HoneyPopsの発売を発表しました。ハニーポップスはカナダのプリンスエドワード島で製造され、カナダ産ハチミツ、メントール、天然フレーバー、天然色素を含む最大4種類の天然素材を使用しています。砂糖は無添加で、子供向けのチェリー、ストロベリー、レモン、ナチュラルハニーの4種類があります。

OTC医薬品の需要増加が咽頭炎治療薬市場の成長を牽引する見込み

OTC医薬品の需要が増加しており、予測期間中に市場を牽引すると予想されます。のど飴、スプレー、さまざまな種類の医薬品、鎮痛剤などの咽頭炎治療用OTC医薬品は、病院、オンライン薬局、小売薬局、スーパーマーケット、コンビニエンスストアなどで簡単に入手できます。処方箋がなくても、病院や診療所に行かなくてもOTC製品を購入できるため、すぐに症状を緩和したい場合に便利です。

例えば、2021年11月1日、信頼のおけるOTC咳・風邪薬ブランドであるムシネックスは、のどの痛みを麻痺させ、和らげ、緩和するように設計されたトローチとスプレーを含む新製品ラインであるムシネックス・インスタ・スーチの発売を発表しました。新製品には、Mucinex InstaSoothe Sore Throat+Soothing Comfort Lozenges、Mucinex InstaSoothe Sore Throat+Cough Relief Lozenges、Mucinex InstaSoothe Sore Throat+Pain Relief Sprayがあります。

さらに、OTC医薬品は、咽頭炎に伴う炎症、不快感、のどの痛みなどの一般的な症状を迅速に緩和する能力があります。この迅速な緩和は、即効性のある症状管理を求める人には特に魅力的です。処方箋なしで広く入手できることも、OTC医薬品の大きな要因です。

抗生物質に伴う重篤な副作用が市場の成長を妨げる

抗生物質には中等度から重度の副作用があり、これが予測期間中の市場成長の妨げになると予想されます。下痢、発疹、めまいなどの副作用は、抗生物質を多く使用する患者に最もよく見られます。また、抗生物質による副作用は最長で2カ月続くこともあり、他の種類の感染症を引き起こす可能性もあります。

さらに、抗生物質は他の薬と同様に、副作用や副反応を引き起こす可能性があります。これらは軽度の胃腸障害から重篤なアレルギー反応まで様々で、抗生物質の使用や治療を受けることを躊躇させる。また、抗生物質は体内の正常な微生物叢を破壊するため、イースト菌感染症やその他の日和見感染症などの二次感染のリスクを高める可能性もあります。

代替治療オプションの利用可能性も市場成長の妨げになると予想される

代替治療オプションの利用可能性は、予測期間における市場成長の妨げになると予想されます。咽頭炎患者の多くは、薬の副作用を避けるために、蜂蜜、生姜、ハーブティーなどのハーブ製品、その他のエッセンシャルオイルなどの自然療法に注目しており、これが市場成長の妨げとなっています。

さらに、多くの患者は、医薬品に関連する中程度から重度の副作用を避けるために、治療薬を使用する代わりに、ビタミンCの豊富な果物、辛い食べ物の回避、より多くの水分の摂取などの食事物質に注目し、採用しています。これにより、副作用が少ない、あるいは全くない状態で喉の痛みを軽減することができます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新規治療薬に対する需要の増加
      • OTC医薬品の需要増加
    • 抑制要因
      • 抗生物質に伴う重大な副作用
      • 代替治療オプションの利用可能性
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 疾患タイプ別

  • 急性咽頭炎
  • 慢性咽頭炎

第8章 薬剤クラス別

  • 抗生物質
  • 抗ウイルス薬
  • 副腎皮質ステロイド薬
  • 抗真菌薬
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Novartis
  • Amneal Pharmaceuticals LLC
  • Kenvue Inc.
  • Thornton & Ross Ltd
  • Reckitt Benckiser Group Plc
  • Honibe
  • Prestige Consumer Healthcare Inc.
  • Traditional Medicinals, Inc.
  • Lozen Pharma Pvt. Ltd

第13章 付録

目次
Product Code: PH6750

Market Overview

Global Pharyngitis Treatment Market reached US$ 2.3 billion in 2022 and is expected to reach US$ 3.2 billion by 2030, growing with a CAGR of 4.5% during the forecast period 2023-2030.

The global pharyngitis treatment market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics such as increasing prevalence, increasing demand for novel therapeutics, rising clinical trials, and others. Government investments in novel treatment procedures will continue to drive and boost the global market. The global pharyngitis treatment industry is placing increasing emphasis to reduce its impact.

Pharyngitis also known as sore throat, has two types acute pharyngitis and chronic pharyngitis. The treatment is based on the type and severity of the disease. Many drugs such as antibiotics, NSAIDs, antifungal drugs, antiviral drugs, corticosteroids, antitussives, and others are used in the treatment of sore throat. But antibiotics are considered first-line treatment drugs. Similarly, North America dominates the global market by capturing the largest market share owing to the advanced healthcare infrastructure and presence of major players.

Owing to the increasing prevalence of pharyngitis or sore throat, growing awareness, increasing demand for novel therapeutics, rising clinical trials, increasing adoption of personalized medicines, increasing demand for Over-the-Counter (OTC) medicines, and advancements in treatment options are the major factors expected to drive market over the forecast period.

Market Dynamics

Increasing Demand for Novel Therapeutics is Expected to Drive the Growth of the Pharyngitis Treatment Market

There is an increasing demand for novel therapeutics, which is expected to drive the global market over the forecast period. The currently available pharyngitis treatments and therapeutics are the most widely used, especially antibiotics, but there are also some side effects associated with these drugs. Novel therapeutics are continuously evolving with better patient outcomes, and there is continuously increasing demand for innovative products which have minimal side effects.

For instance, on May 16, 2022, Vicks announced the launch of Vicks Tulsi cough drops in India. By adding Tulsi flavor to its range of products, the brand reaffirms its aim of making traditional remedies, passed down by generations, convenient and accessible to all with very less side effects compared to other medications.

Moreover, the ongoing research activities on pharyngitis therapeutics enhance the opportunities for better treatment, and the development of innovative treatment approaches has led to the discovery of potential novel therapeutic options which are very suitable for all ages including kids. These advancements increase the way for the introduction of novel drugs with different mechanisms of action.

For instance, on February 11, 2021, Honibe announced the launch of HoneyPops, the first (up to) 99% pure honey lollipop for kids that soothes sore throats naturally. HoneyPops are manufactured in Prince Edward Island, Canada, using up to four all-natural ingredients including Canadian honey, menthol, natural flavor, and natural color. They have no added sugar and are available in kid-friendly cherry, strawberry, lemon, and natural honey.

Increasing Demand for OTC Medicines Expected to Drive the Growth of the Pharyngitis Treatment Market

There is an increasing demand for OTC medications which is expected to drive the market over the forecast period. OTC medications for pharyngitis, such as throat lozenges, sprays, different types of drugs, and pain relievers, are readily available in the hospital, online and retail pharmacies, supermarkets, and convenience stores. Patients can purchase OTC products without a prescription or a visit to a hospital or clinic, making them convenient for immediate symptom relief.

For instance, on November 1, 2021, Mucinex, the trusted OTC cough and cold brand announced the launch of Mucinex InstaSoothe, a new product line inclusive of lozenges and spray designed to numb, soothe, and relieve sore throat pain. The new products include Mucinex InstaSoothe Sore Throat + Soothing Comfort Lozenges, Mucinex InstaSoothe Sore Throat + Cough Relief Lozenges, and Mucinex InstaSoothe Sore Throat + Pain Relief Spray.

Moreover, OTC medications have the ability to provide rapid relief for common symptoms like irritation, discomfort, and sore throat which are associated with pharyngitis. This quick relief can be particularly appealing to individuals looking for immediate symptom management. Their wide availability without prescription is also a major factor for OTC medicines.

Severe Side Effects Associated with Antibiotics Will Hamper the Market's Growth

There are moderate to severe side effects associated with the antibiotics, which are expected to hamper the market growth over the forecast period. Side effects such as diarrhea, rashes, dizziness, and other adverse effects are most commonly seen in patients who are using more antibiotics. And the side effects caused by the antibiotics may last up to 2 months, which may cause other types of infections.

Furthermore, antibiotics, like all medications, can cause adverse reactions and side effects. These can range from mild gastrointestinal disturbances to more serious allergic reactions, which can deter individuals from using antibiotics and seeking treatment. Antibiotics can also increase the risk of secondary infections such as yeast infections or other opportunistic infections due to the disruption of the body's normal microbial flora.

The Availability of Alternative Treatment Options Will Also be Expected to Hamper the Market Growth

The availability of alternative treatment options is expected to hamper the market growth over the forecast period. Many individuals with pharyngitis are focussing on natural remedies such as honey, ginger, herbal products like herbal tea, and other essential oils to avoid the adverse effects of the drugs, which in turn hamper the market growth.

Additionally, many patients are focussing on and adopting dietary substances like vitamin C-rich fruits, avoiding spicy food, and consuming more fluids instead of using pharmaceutical therapeutics to skip the moderate to severe side effects associated with pharmaceutical drugs. This may helps to reduce the sore throat with lesser or no side effects.

Segment Analysis

The global pharyngitis treatment market is segmented based on disease type, drug class, distribution channel and region.

The Antibiotics Segment Accounted for Approximately 36.8% of the Market Share

Antibiotics are expected to hold the largest market share over the forecast period owing to their wide availability and acceptability. Antibiotics have the ability to provide rapid relief from pharyngitis symptoms by targeting the underlying infection, and results in quick and rapid relief from sore throat, penicillin and its derivatives, such as amoxicillin, are often prescribed as the first-line antibiotics. This can be especially important for individuals who have severe symptoms or those who need to recover quickly.

Moreover, antibiotics are more commonly used for the treatment of pharyngitis, especially when the condition is caused by bacterial infections, such as streptococcal bacteria. Group A Streptococcus (Streptococcus pyogenes) is a common bacterial pathogen that causes streptococcal pharyngitis, also known as strep throat (type of pharyngitis). Antibiotics are effective in treating bacterial infections and can help alleviate symptoms, prevent complications, and reduce the spread of infection to others.

For instance, according to the Centers for Disease Control and Prevention, Penicillin or amoxicillin is the antibiotic of choice to treat group A strep pharyngitis. However, resistance to azithromycin and clarithromycin is common in some communities. For patients with a penicillin allergy, recommended regimens include narrow-spectrum cephalosporins (cephalexin, cefadroxil), clindamycin, azithromycin, and clarithromycin.

Geographical Penetration

North America Accounted for Approximately 37.7% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Favourable Reimbursement Policies

North America is expected to hold the largest market share over the forecast period owing to the advanced healthcare infrastructure and favorable reimbursement policies. North America especially the United States and Canada is known for its advanced and well-established healthcare infrastructure including hospitals, specialty clinics, ENT clinics, and others which offers better treatment and therapeutics for fast and quick relief from pharyngitis.

Moreover, due to the region's high population, there is a high prevalence of pharyngitis, this increased prevalence increases the demand for novel therapeutics. North America offers favorable reimbursement policies for these novel therapeutics enhancing improved patient outcomes. This improved insurance coverage and reimbursement policies offers the better treatment for many patients at affordable costs, leading to market dominance in the region.

Competitive Landscape

The major global players in the pharyngitis treatment market include Pfizer Inc., Novartis, Amneal Pharmaceuticals LLC, Kenvue Inc., Thornton & Ross Ltd, Reckitt Benckiser Group Plc, Honibe, Prestige Consumer Healthcare Inc., Traditional Medicinals, Inc., and Lozen Pharma Pvt. Ltd among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global pharyngitis treatment market. During the pandemic, regulatory approvals for innovative treatments for pharyngitis treatment have been temporarily postponed due to the redirected focus towards the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations of pharyngitis patients due to the similar symptoms associated with COVID-19. Many hospitals are focused on COVID-19 cases, due to the similar symptom, and the focus on sore throat has increased to reduce the severity.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as antibiotics and other drugs. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks. Furthermore, telemedicine is a positive approach resulted from the COVID-19 pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global pharyngitis treatment market. The conflict has less impact on the market mainly due to the low prevalence and absence of key market players in this region and the impact of the import and export of raw materials such as different types of drugs.

By Disease Type

  • Acute Pharyngitis
  • Chronic Pharyngitis

By Drug Class

  • Antibiotics
  • Antiviral Drugs
  • Corticosteroids
  • Antifungals
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • On May 25, 2023, Traditional Medicinals, a leading botanical wellness company with more than 60 high-quality teas, lozenges, and capsules, announced a partnership with Dave Matthews Band through sponsorship of REVERB's Eco-Village during the band's U.S. summer concert tour. Dave Matthews has been using Throat Coat tea for years, as part of his throat care routine before performing and while onstage sharing his music with fans. Through his connection to the Throat Coat brand and REVERB's mission to empower the music community to take meaningful environmental action, Traditional Medicinals saw a values-aligned opportunity to connect people, plants, and the planet through this partnership.
  • On January 10, 2022, Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial-1 which compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19 and their related diseases including sore throat, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefits over placebo.

DataM Intelligence Opinion:

According to the DataM Intelligence, the pharyngitis treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence, increasing adoption of natural therapeutics, increasing adoption of OTC medicines, and their wide availability. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many research activities are still going on for novel therapeutics for quick relief from sore throat, which is expected to growth of the global pharyngitis treatment market in the upcoming years.

Why Purchase the Report?

  • To visualize the global pharyngitis treatment market segmentation based on disease type, drug class, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pharyngitis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pharyngitis treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Novel Therapeutics
      • 4.1.1.2. Increasing Demand for OTC Medicines
    • 4.1.2. Restraints
      • 4.1.2.1. Sever Side Effects Associated with Antibiotics
      • 4.1.2.2. Availability of Alternative Treatment Options
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine Conflict Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Acute Pharyngitis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Chronic Pharyngitis

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Antibiotics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Antiviral Drugs
  • 8.4. Corticosteroids
  • 8.5. Antifungals
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Russia
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Novartis
  • 12.3. Amneal Pharmaceuticals LLC
  • 12.4. Kenvue Inc.
  • 12.5. Thornton & Ross Ltd
  • 12.6. Reckitt Benckiser Group Plc
  • 12.7. Honibe
  • 12.8. Prestige Consumer Healthcare Inc.
  • 12.9. Traditional Medicinals, Inc.
  • 12.10. Lozen Pharma Pvt. Ltd

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us